SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing a massive parabolic surge following positive comments from Nvidia's CEO regarding the company's long-term potential in AI infrastructure and connectivity. While bullish investors are aggressively buying on momentum, community sentiment remains highly polarized, with many traders debating whether this movement is a justified valuation shift or a speculative bubble prone to a sharp reversal.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a surprise early release of strong first-quarter financial results alongside a two-billion-dollar share buyback authorization. Community sentiment is deeply divided, with many investors highlighting the company's improved profitability and cash position, while others remain skeptical, debating the potential for future share dilution and the company's recent strategic pivot toward eBay.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors digest a series of aggressive analyst price target upgrades alongside broader sector volatility triggered by competitor product announcements in the AI PC space. The community remains deeply divided, with many bulls viewing current pullbacks as tactical buying opportunities for long-term growth while some bears cite concerns over valuation multiples compared to AI market leaders.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently the focal point of intense community debate and institutional hedging as traders weigh the company's long-term turnaround potential against Nvidia's recent aggressive expansion into the CPU and PC processor markets. Investors are closely monitoring key industry conferences and leadership commentary for catalysts that could stabilize recent volatility or trigger a breakout from current technical support levels.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing a massive surge in volume and price as the community rallies around its pivot to physical AI and automotive software via the QNX platform. Investors are actively discussing a potential short squeeze and viewing the recent momentum as a fundamental re-rating of the companys growth prospects.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The community is debating the sustainability of the semiconductor sector's parabolic rally, with many investors actively discussing the extreme technical overextension and the influence of AI-related hype on stock valuations. Traders are split between attempting to catch a bottom in the inverse-leveraged SOXS and fearing further decay due to persistent bullish momentum and market-maker positioning.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is seeing increased volatility after its latest earnings report, which highlighted strong revenue growth and AI-driven security demand despite market concerns over high valuation and inorganic growth from acquisitions. The community is actively debating the stock's long-term potential versus immediate risks, with many traders discussing whether recent gains are sustainable or if the company is overdue for a price correction.

The WalletConnect Network is the onchain UX ecosystem. It is the open and decentralized network that enables users to connect to apps across the globe. It continues to power over 15M monthly connections for users across the world's leading decentralized applications and 300+ chains. In the past 12 months, the WalletConnect Network has grown by over 240%. Simply put, the WalletConnect Network plays a critical role in the $2+ trillion that flows throughout web3 today.

WalletConnect Token

WalletConnect Token is drawing significant attention from investors as it experiences heightened volatility, with community members actively discussing its potential for a breakout and debating the impact of centralized exchange listings. Sentiment remains divided, as some traders highlight the token's integration within the broader crypto ecosystem while others remain cautious of frequent price manipulation and whale activity.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The iShares Bitcoin ETF is seeing heightened trading volume and community discourse as investors debate whether recent price movements signal a sustainable bullish breakout or another trap for those chasing upside. Discussion is centered on the interplay between broader market volatility, institutional accumulation patterns, and the impact of evolving crypto-focused legislative developments on the asset's long-term trajectory.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors scrutinize the company's lack of transparent communication regarding clinical pipeline updates and potential acquisition strategies under new CEO Kevin Tang. Community discussion is focused on analyzing recent SEC filings, monitoring institutional accumulation, and debating the stocks price action ahead of the upcoming Annual General Meeting.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus Inc. (Agenus) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET. To participate in...

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

How Agenus' Pipeline Progress Unlock Its Next Growth Phase

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetiks artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology...

AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -51.43% and -73.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

AGENAgenus Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGEN News